China may be developing a booster injection for people who have been fully vaccinated against COVID-19, while the vaccines of Sinopharm and Kexing may be less effective.
China Shanghai Fosun Pharma (Fosun Pharma) has cooperated with BioNTech to develop mRNA booster vaccines. After the expert panel review by the Chinese drug regulatory agency, the lens has now entered the administrative review stage. Caixin Global Report.
The booster’s brand name is Kang Mei Le, and it may start domestic trial production at the end of August, and it can be provided free of charge to people who have received Sinopharm and Konok injections.
Health experts say that the development of enhanced injections may be seen as a blow to the Chinese government, which has been touting the effectiveness of its vaccines.
“I think Chinese scientists are also aware of the fact that antibodies are low [levels] In the serum of Sinovac or Sinopharm vaccine.Therefore, they may imply that the Chinese government has another shot as a booster,” Shi Xinru, director of the Center for Emerging Virus Infection Research, told Voice of America Mandarin.
After a study published in Hong Kong, China began to discuss boosting vaccines Lancet It was discovered on July 15 that the COVID-19 vaccine developed by Pfizer-BioNTech provided recipients with 10 times the antibody level of the Sinovac COVID-19 vaccine.
The researchers stated that the antibody levels of the 63 participants who received Pfizer injections “increased sharply after the first dose of vaccine, and then rose again after the second dose of vaccine.” The study found that in contrast, 30 participants received Sinovac injections. The antibody level of a health care worker was “low antibody concentration… after the first dose, it rose to a moderate concentration after the second dose.”
Published in another Medicine Magazine On Monday, researchers found that the Sinopharm COVID-19 vaccine had a weaker antibody response to the more infectious Delta variant.
According to scientists, the level of antibodies in people who took the Chinese Medicine Pill was 1.38 times lower than that of normal people. Delta variant Compared with the original strain of COVID-19. The study also found that after the vaccine was injected, the antibody levels of people who developed the Beta variant were reduced by 10 times.
A Hong Kong study showed that people who received the BioNTech coronavirus vaccine had ten times the number of antibodies than people who received Sinovac
Photo: AFP/Anthony Wallace
